Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions: an international study
Background: The utility of measuring non-vitamin K antagonist oral anticoagulants (NOACs) in plasma, serum and urine samples and with the point-of-care test (POCT) on urine samples should be analysed in an international laboratory study. Methods: The study was performed to determine the inter-labora...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2016
|
| In: |
Clinical chemistry and laboratory medicine
Year: 2016, Jahrgang: 54, Heft: 2, Pages: 275-283 |
| ISSN: | 1437-4331 |
| DOI: | 10.1515/cclm-2015-0389 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1515/cclm-2015-0389 Verlag, Volltext: https://www-degruyter-com.ezproxy.medma.uni-heidelberg.de/view/j/cclm.2016.54.issue-2/cclm-2015-0389/cclm-2015-0389.xml 
|
| Verfasserangaben: | Job Harenberg, Shanshan Du, Martin Wehling, Shabnam Zolfaghari, Christel Weiss, Roland Krämer, Jeanine Walenga |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1586667165 | ||
| 003 | DE-627 | ||
| 005 | 20230427034219.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190129s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/cclm-2015-0389 |2 doi | |
| 035 | |a (DE-627)1586667165 | ||
| 035 | |a (DE-576)516667165 | ||
| 035 | |a (DE-599)BSZ516667165 | ||
| 035 | |a (OCoLC)1341034415 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Harenberg, Job |d 1950- |e VerfasserIn |0 (DE-588)108825507 |0 (DE-627)655891498 |0 (DE-576)339563745 |4 aut | |
| 245 | 1 | 0 | |a Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions |b an international study |c Job Harenberg, Shanshan Du, Martin Wehling, Shabnam Zolfaghari, Christel Weiss, Roland Krämer, Jeanine Walenga |
| 264 | 1 | |c 2016 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 29.01.2019 | ||
| 500 | |a Online erschienen: 09.07.2015 | ||
| 520 | |a Background: The utility of measuring non-vitamin K antagonist oral anticoagulants (NOACs) in plasma, serum and urine samples and with the point-of-care test (POCT) on urine samples should be analysed in an international laboratory study. Methods: The study was performed to determine the inter-laboratory variance of data from two chromogenic assays each for the NOACs rivaroxaban, apixaban and dabigatran, and to analyse the sensitivity and specificity of the POCT assays for factor Xa- and thrombin inhibitors. Plasma, serum and urine samples were taken from six patients in each group on treatment with a NOAC. Results: The inter-laboratory variances, which can be identified best by the coefficient of variation, ranged from 46% to 59% for apixaban, 63% to 73% for rivaroxaban and 39% to 104% for dabigatran using plasma, serum or urine samples and two chromogenic assays for each NOAC. The concentrations were about 20% higher in serum compared to plasma samples for apixaban and rivaroxaban, and 60% lower for dabigatran. The concentration in urine samples was five-fold (apixaban), 15-fold (rivaroxaban) and 50-fold (dabigatran) higher. Sensitivity and specificity of POCT for apixaban, rivaroxaban, and dabigatran were all >94%. Conclusions: The inter-laboratory study showed the feasibility of measurement of apixaban, rivaroxaban, and dabigatran in plasma, serum and urine samples of patients on treatment. Dabigatran was determined at far lower levels in serum compared to plasma samples. Concentrations of NOACs in urine were much higher compared to plasma. The POCT was highly sensitive and specific for all three NOACs | ||
| 650 | 4 | |a anticoagulants | |
| 650 | 4 | |a antithrombins | |
| 650 | 4 | |a clinical chemistry tests | |
| 650 | 4 | |a direct factor Xa inhibitors | |
| 650 | 4 | |a plasma | |
| 650 | 4 | |a point-of-care systems | |
| 650 | 4 | |a serum | |
| 650 | 4 | |a urine | |
| 700 | 1 | |a Wehling, Martin |d 1957- |e VerfasserIn |0 (DE-588)129939331 |0 (DE-627)484463152 |0 (DE-576)297912577 |4 aut | |
| 700 | 1 | |a Weiß, Christel |d 1958- |e VerfasserIn |0 (DE-588)123287707 |0 (DE-627)082463417 |0 (DE-576)168356104 |4 aut | |
| 700 | 1 | |a Krämer, Roland |e VerfasserIn |0 (DE-588)1020469730 |0 (DE-627)691227861 |0 (DE-576)360500331 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d Berlin [u.a.] : De Gruyter, 1998 |g 54(2016), 2, Seite 275-283 |h Online-Ressource |w (DE-627)302923187 |w (DE-600)1492732-9 |w (DE-576)088704882 |x 1437-4331 |7 nnas |a Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions an international study |
| 773 | 1 | 8 | |g volume:54 |g year:2016 |g number:2 |g pages:275-283 |g extent:9 |a Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions an international study |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/cclm-2015-0389 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www-degruyter-com.ezproxy.medma.uni-heidelberg.de/view/j/cclm.2016.54.issue-2/cclm-2015-0389/cclm-2015-0389.xml |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190129 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 108825507 |a Harenberg, Job |m 108825507:Harenberg, Job |d 60000 |e 60000PH108825507 |k 0/60000/ |p 1 |x j | ||
| 998 | |g 1020469730 |a Krämer, Roland |m 1020469730:Krämer, Roland |d 120000 |d 120200 |e 120000PK1020469730 |e 120200PK1020469730 |k 0/120000/ |k 1/120000/120200/ |p 6 | ||
| 998 | |g 123287707 |a Weiß, Christel |m 123287707:Weiß, Christel |d 60000 |d 60200 |d 60250 |e 60000PW123287707 |e 60200PW123287707 |e 60250PW123287707 |k 0/60000/ |k 1/60000/60200/ |k 2/60000/60200/60250/ |p 5 | ||
| 998 | |g 129939331 |a Wehling, Martin |m 129939331:Wehling, Martin |d 60000 |d 65400 |e 60000PW129939331 |e 65400PW129939331 |k 0/60000/ |k 1/60000/65400/ |p 3 | ||
| 999 | |a KXP-PPN1586667165 |e 3049890134 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"9 S."}],"recId":"1586667165","origin":[{"dateIssuedDisp":"2016","dateIssuedKey":"2016"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"recId":"302923187","disp":"Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions an international studyClinical chemistry and laboratory medicine","origin":[{"dateIssuedKey":"1998","publisherPlace":"Berlin [u.a.]","dateIssuedDisp":"1998-","publisher":"De Gruyter"}],"note":["Gesehen am 22.6.2022"],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title_sort":"Clinical chemistry and laboratory medicine","title":"Clinical chemistry and laboratory medicine"}],"pubHistory":["36.1998-"],"titleAlt":[{"title":"CCLM"}],"name":{"displayForm":["publ. in association with the International Federation of Clinical Chemistry and Laboratory Medicine and the Forum of the European Societies of Clinical Chemistry"]},"part":{"volume":"54","year":"2016","issue":"2","extent":"9","text":"54(2016), 2, Seite 275-283","pages":"275-283"},"id":{"eki":["302923187"],"issn":["1437-4331"],"doi":["10.1515/cclm"],"zdb":["1492732-9"]}}],"person":[{"given":"Job","role":"aut","family":"Harenberg","display":"Harenberg, Job"},{"display":"Wehling, Martin","family":"Wehling","role":"aut","given":"Martin"},{"display":"Weiß, Christel","role":"aut","given":"Christel","family":"Weiß"},{"display":"Krämer, Roland","family":"Krämer","role":"aut","given":"Roland"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 29.01.2019","Online erschienen: 09.07.2015"],"title":[{"title":"Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions","title_sort":"Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions","subtitle":"an international study"}],"name":{"displayForm":["Job Harenberg, Shanshan Du, Martin Wehling, Shabnam Zolfaghari, Christel Weiss, Roland Krämer, Jeanine Walenga"]},"id":{"doi":["10.1515/cclm-2015-0389"],"eki":["1586667165"]}} | ||
| SRT | |a HARENBERGJMEASUREMEN2016 | ||